Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections

Yusuke Tanigawara, Mitsuo Kaku, Kyoichi Totsuka, Hiroyuki Tsuge, Atsushi Saito

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

An optimal dosage regimen of sitafloxacin was considered based on a pharmacokinetics and pharmacodynamics (PK-PD) analysis in patients with community-acquired respiratory tract infections (RTI). A population pharmacokinetic analysis of sitafloxacin was conducted using clinical data of five clinical pharmacology studies and one clinical PK-PD study in patients with RTIs. The pharmacokinetic parameters in individual patients were estimated by the Bayesian method to examine any correlation between pharmacokinetics and bacteriological efficacy. Efficacy data were obtained from the clinical PK-PD study, in which 50 or 100 mg sitafloxacin was administered twice daily for 7 days. In addition, an efficacy was simulated for a hypothetical dose regimen of 100 mg once daily. The fAUC0-24h/MIC and the fC max/MIC of sitafloxacin at a dose of 50 mg twice daily were 117.5 ± 78.0 and 7.3 ± 4.7 (mean ± SD), respectively. As a result of the univariate logistic regression analysis, the larger the value of fAUC0-24h/MIC or fC max/MIC becomes, the higher the bacteriological efficacies. The eradication rates for fAUC0-24h/MIC ≥ 30 and for fC max/MIC ≥ 2 were 96.4 % and 96.3 %, respectively. The PK-PD target values of sitafloxacin for the treatment of mild to moderate RTIs were considered to be fAUC0-24h/MIC ≥ 30 and fC max/MIC ≥ 2. The PK-PD parameters at the regimen of 50 or 100 mg twice daily in patients with RTIs reached the target values. Furthermore, a 100 mg once-daily regimen was expected to show similar efficacy based on the PK-PD simulations.

Original languageEnglish
Pages (from-to)858-866
Number of pages9
JournalJournal of Infection and Chemotherapy
Volume19
Issue number5
DOIs
Publication statusPublished - 2013 Oct

Fingerprint

Community-Acquired Infections
Respiratory Tract Infections
Pharmacokinetics
Population
sitafloxacin
Bayes Theorem
Clinical Pharmacology
Logistic Models
Regression Analysis

Keywords

  • Optimal dosage regimen
  • Population PK-PD
  • Sitafloxacin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. / Tanigawara, Yusuke; Kaku, Mitsuo; Totsuka, Kyoichi; Tsuge, Hiroyuki; Saito, Atsushi.

In: Journal of Infection and Chemotherapy, Vol. 19, No. 5, 10.2013, p. 858-866.

Research output: Contribution to journalArticle

@article{d276cff0c06e4b75a9e4d9d561d6b4b2,
title = "Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections",
abstract = "An optimal dosage regimen of sitafloxacin was considered based on a pharmacokinetics and pharmacodynamics (PK-PD) analysis in patients with community-acquired respiratory tract infections (RTI). A population pharmacokinetic analysis of sitafloxacin was conducted using clinical data of five clinical pharmacology studies and one clinical PK-PD study in patients with RTIs. The pharmacokinetic parameters in individual patients were estimated by the Bayesian method to examine any correlation between pharmacokinetics and bacteriological efficacy. Efficacy data were obtained from the clinical PK-PD study, in which 50 or 100 mg sitafloxacin was administered twice daily for 7 days. In addition, an efficacy was simulated for a hypothetical dose regimen of 100 mg once daily. The fAUC0-24h/MIC and the fC max/MIC of sitafloxacin at a dose of 50 mg twice daily were 117.5 ± 78.0 and 7.3 ± 4.7 (mean ± SD), respectively. As a result of the univariate logistic regression analysis, the larger the value of fAUC0-24h/MIC or fC max/MIC becomes, the higher the bacteriological efficacies. The eradication rates for fAUC0-24h/MIC ≥ 30 and for fC max/MIC ≥ 2 were 96.4 {\%} and 96.3 {\%}, respectively. The PK-PD target values of sitafloxacin for the treatment of mild to moderate RTIs were considered to be fAUC0-24h/MIC ≥ 30 and fC max/MIC ≥ 2. The PK-PD parameters at the regimen of 50 or 100 mg twice daily in patients with RTIs reached the target values. Furthermore, a 100 mg once-daily regimen was expected to show similar efficacy based on the PK-PD simulations.",
keywords = "Optimal dosage regimen, Population PK-PD, Sitafloxacin",
author = "Yusuke Tanigawara and Mitsuo Kaku and Kyoichi Totsuka and Hiroyuki Tsuge and Atsushi Saito",
year = "2013",
month = "10",
doi = "10.1007/s10156-013-0580-2",
language = "English",
volume = "19",
pages = "858--866",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections

AU - Tanigawara, Yusuke

AU - Kaku, Mitsuo

AU - Totsuka, Kyoichi

AU - Tsuge, Hiroyuki

AU - Saito, Atsushi

PY - 2013/10

Y1 - 2013/10

N2 - An optimal dosage regimen of sitafloxacin was considered based on a pharmacokinetics and pharmacodynamics (PK-PD) analysis in patients with community-acquired respiratory tract infections (RTI). A population pharmacokinetic analysis of sitafloxacin was conducted using clinical data of five clinical pharmacology studies and one clinical PK-PD study in patients with RTIs. The pharmacokinetic parameters in individual patients were estimated by the Bayesian method to examine any correlation between pharmacokinetics and bacteriological efficacy. Efficacy data were obtained from the clinical PK-PD study, in which 50 or 100 mg sitafloxacin was administered twice daily for 7 days. In addition, an efficacy was simulated for a hypothetical dose regimen of 100 mg once daily. The fAUC0-24h/MIC and the fC max/MIC of sitafloxacin at a dose of 50 mg twice daily were 117.5 ± 78.0 and 7.3 ± 4.7 (mean ± SD), respectively. As a result of the univariate logistic regression analysis, the larger the value of fAUC0-24h/MIC or fC max/MIC becomes, the higher the bacteriological efficacies. The eradication rates for fAUC0-24h/MIC ≥ 30 and for fC max/MIC ≥ 2 were 96.4 % and 96.3 %, respectively. The PK-PD target values of sitafloxacin for the treatment of mild to moderate RTIs were considered to be fAUC0-24h/MIC ≥ 30 and fC max/MIC ≥ 2. The PK-PD parameters at the regimen of 50 or 100 mg twice daily in patients with RTIs reached the target values. Furthermore, a 100 mg once-daily regimen was expected to show similar efficacy based on the PK-PD simulations.

AB - An optimal dosage regimen of sitafloxacin was considered based on a pharmacokinetics and pharmacodynamics (PK-PD) analysis in patients with community-acquired respiratory tract infections (RTI). A population pharmacokinetic analysis of sitafloxacin was conducted using clinical data of five clinical pharmacology studies and one clinical PK-PD study in patients with RTIs. The pharmacokinetic parameters in individual patients were estimated by the Bayesian method to examine any correlation between pharmacokinetics and bacteriological efficacy. Efficacy data were obtained from the clinical PK-PD study, in which 50 or 100 mg sitafloxacin was administered twice daily for 7 days. In addition, an efficacy was simulated for a hypothetical dose regimen of 100 mg once daily. The fAUC0-24h/MIC and the fC max/MIC of sitafloxacin at a dose of 50 mg twice daily were 117.5 ± 78.0 and 7.3 ± 4.7 (mean ± SD), respectively. As a result of the univariate logistic regression analysis, the larger the value of fAUC0-24h/MIC or fC max/MIC becomes, the higher the bacteriological efficacies. The eradication rates for fAUC0-24h/MIC ≥ 30 and for fC max/MIC ≥ 2 were 96.4 % and 96.3 %, respectively. The PK-PD target values of sitafloxacin for the treatment of mild to moderate RTIs were considered to be fAUC0-24h/MIC ≥ 30 and fC max/MIC ≥ 2. The PK-PD parameters at the regimen of 50 or 100 mg twice daily in patients with RTIs reached the target values. Furthermore, a 100 mg once-daily regimen was expected to show similar efficacy based on the PK-PD simulations.

KW - Optimal dosage regimen

KW - Population PK-PD

KW - Sitafloxacin

UR - http://www.scopus.com/inward/record.url?scp=84885957538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885957538&partnerID=8YFLogxK

U2 - 10.1007/s10156-013-0580-2

DO - 10.1007/s10156-013-0580-2

M3 - Article

C2 - 23529500

AN - SCOPUS:84885957538

VL - 19

SP - 858

EP - 866

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 5

ER -